Insufficient scRNA-seq data for expression of MRGPRX2 at single-cell level.
Insufficient scRNA-seq data for expression of MRGPRX2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 86% | 32.48 | 18 / 21 | 6% | 0.15 | 32 / 504 |
skin | 68% | 66.68 | 1229 / 1809 | 0% | 0.00 | 1 / 472 |
adipose | 64% | 43.42 | 774 / 1204 | 0% | 0 | 0 / 0 |
esophagus | 59% | 27.83 | 851 / 1445 | 2% | 0.03 | 3 / 183 |
breast | 59% | 20.60 | 273 / 459 | 0% | 0.01 | 3 / 1118 |
intestine | 44% | 10.61 | 421 / 966 | 0% | 0.00 | 1 / 527 |
stomach | 29% | 6.41 | 104 / 359 | 0% | 0 | 0 / 286 |
uterus | 27% | 5.83 | 46 / 170 | 0% | 0.01 | 2 / 459 |
prostate | 17% | 3.67 | 41 / 245 | 0% | 0 | 0 / 502 |
muscle | 14% | 2.18 | 109 / 803 | 0% | 0 | 0 / 0 |
lung | 12% | 1.89 | 68 / 578 | 1% | 0.01 | 10 / 1155 |
peripheral blood | 9% | 1.33 | 79 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 8% | 1.53 | 111 / 1335 | 0% | 0 | 0 / 0 |
heart | 7% | 0.83 | 57 / 861 | 0% | 0 | 0 / 0 |
spleen | 6% | 0.59 | 14 / 241 | 0% | 0 | 0 / 0 |
kidney | 3% | 0.51 | 3 / 89 | 0% | 0.00 | 2 / 901 |
ovary | 3% | 0.46 | 6 / 180 | 0% | 0.00 | 1 / 430 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
thymus | 1% | 0.19 | 8 / 653 | 1% | 0.01 | 4 / 605 |
liver | 1% | 0.20 | 3 / 226 | 0% | 0.01 | 1 / 406 |
brain | 0% | 0.01 | 3 / 2642 | 0% | 0.00 | 1 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 0% | 0 | 0 / 230 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
pancreas | 0% | 0 | 0 / 328 | 0% | 0 | 0 / 178 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019233 | Biological process | sensory perception of pain |
GO_0043303 | Biological process | mast cell degranulation |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0032467 | Biological process | positive regulation of cytokinesis |
GO_0030431 | Biological process | sleep |
GO_0045576 | Biological process | mast cell activation |
GO_0016020 | Cellular component | membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0042923 | Molecular function | neuropeptide binding |
GO_1990595 | Molecular function | mast cell secretagogue receptor activity |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
Gene name | MRGPRX2 |
Protein name | Mas-related G-protein coupled receptor member X2 |
Synonyms | MRGX2 |
Description | FUNCTION: Mast cell-specific receptor for basic secretagogues, i.e. cationic amphiphilic drugs, as well as endo- or exogenous peptides, consisting of a basic head group and a hydrophobic core . Recognizes and binds small molecules containing a cyclized tetrahydroisoquinoline (THIQ), such as non-steroidal neuromuscular blocking drugs (NMBDs), including tubocurarine and atracurium. In response to these compounds, mediates pseudo-allergic reactions characterized by histamine release, inflammation and airway contraction (By similarity). Acts as a receptor for a number of other ligands, including peptides and alkaloids, such as cortistatin-14, proadrenomedullin N-terminal peptides PAMP-12 and, at lower extent, PAMP-20, antibacterial protein LL-37, PMX-53 peptide, beta-defensins, and complanadine A. . |
Accessions | Q96LB1 ENST00000329773.3 |